Normal view MARC view ISBD view

Economic evaluation of hypertension treatment and control in Switzerland [publication] /

by Congouleris Papaioannou, Elisabeth.
Material type: materialTypeLabelBookSeries: Mémoire / Institute of Health Economics and Management ; no 136.Publisher: Lausanne : IEMS (Institute of Health Economics and Management), 2009Description: 32 sheets : fig. ; 30 cm.SAPHIR theme(s): Maladies - Pathologies | Économie de la santéMeSH subject(s): Hypertension | Cost-Benefit Analysis | Hypertension -- drug therapy | Hypertension -- economics | Hypertension -- prevention & control | SwitzerlandPUBLICATION TYPE SAPHIR: DissertationOnline resources: Date de consultation : 16.07.2010 Summary: The data of our analysis were taken from the CoLaus study which was a random selection of Lausanne inhabitants of 35-75 years who were invited to participate. For the Swiss Health Survey the data of individuals of 15 years and over were collected in a cross sectional nation wide population-based telephone survey of 2007. The cost of the antihypertensive drug was taken from the Swiss compendium using the drug treatment registered in the CoLaus study. The minimum, medium, median and maximum price of one drug unit were computed for ail medicines containing the antihypertensive molecule or the combination of molecules in the market. The same calculations were done for ail therapeutic drug treatments. The daily hypertensive treatment per person was multiplied by 365.25 to estimate the yearly treatment. Three scenarios were used, the f1fst one, the more optimistic, considered only one visit to the physician, one ECG, and only one set of biological measurements, added to the drug treatment (median, minimum, maximum). The second scenario considered two medical visits, one ECG and one set of biological measurements. The third scenario, the least optimistic, considered four visits, ECG and biological measurements. These calculations were used to ma).oe extrapolations to the Swiss population using the average number of individuals between 35-75 years living in Switzerland for the years 2003-2007. By using the percentage of the individuals treated and of those treated but not controlled estimates were made for the general population. It was interesting to find that estimates for the CoLaus study and the Swiss Health Survey were very similar. Antihypertensive drug treatment represents the 35-65% of the total antihypertensive management costs of which more than two thirds concerns individuals of 55-75 years. The individual yearly cost of hypertension management was estimated to be 831 CHF for the more optimistic scenario while the least optimistic was estimated to be 1725 CHF. The daily cost was estimated to be over one million to over 2.5 million francs respectively for the general Swiss population. The cost of hypertension management varied greatly if expensive calcium channel blockers or the angiotensin-converting enzyme inhibitors were replaced by thiazides (diuretics) and beta-blockers. [Author, p. 7-8]
Item type Current location Call number Status Date due
IST, Institut universitaire romand de santé au travail; Bibliothèque
PUB-THES-MEM (Browse shelf) Available

The data of our analysis were taken from the CoLaus study which was a random selection of Lausanne inhabitants of 35-75 years who were invited to participate. For the Swiss Health Survey the data of individuals of 15 years and over were collected in a cross sectional nation wide population-based telephone survey of 2007. The cost of the antihypertensive drug was taken from the Swiss compendium using the drug treatment registered in the CoLaus study. The minimum, medium, median and maximum price of one drug unit were computed for ail medicines containing the antihypertensive molecule or the combination of molecules in the market. The same calculations were done for ail therapeutic drug treatments. The daily hypertensive treatment per person was multiplied by 365.25 to estimate the yearly treatment. Three scenarios were used, the f1fst one, the more optimistic, considered only one visit to the physician, one ECG, and only one set of biological measurements, added to the drug treatment (median, minimum, maximum). The second scenario considered two medical visits, one ECG and one set of biological measurements. The third scenario, the least optimistic, considered four visits, ECG and biological measurements. These calculations were used to ma).oe extrapolations to the Swiss population using the average number of individuals between 35-75 years living in Switzerland for the years 2003-2007. By using the percentage of the individuals treated and of those treated but not controlled estimates were made for the general population. It was interesting to find that estimates for the CoLaus study and the Swiss Health Survey were very similar. Antihypertensive drug treatment represents the 35-65% of the total antihypertensive management costs of which more than two thirds concerns individuals of 55-75 years. The individual yearly cost of hypertension management was estimated to be 831 CHF for the more optimistic scenario while the least optimistic was estimated to be 1725 CHF. The daily cost was estimated to be over one million to over 2.5 million francs respectively for the general Swiss population. The cost of hypertension management varied greatly if expensive calcium channel blockers or the angiotensin-converting enzyme inhibitors were replaced by thiazides (diuretics) and beta-blockers. [Author, p. 7-8]